Skip to main content
Premium Trial:

Request an Annual Quote

Cequent Files IND for FAP Drug, Expects Trial to Begin in Early 2010


Cequent Pharmaceuticals said last week that it has filed an investigational new drug application to begin human trials of CEQ508, the company’s orally delivered, RNAi-based treatment for advanced familial adenomatous polyposis.

FAP is an inherited, colorectal cancer syndrome characterized by the growth of colorectal polyps. Though the polyps are initially benign, they become malignant in nearly all cases in the absence of colectomy, according to the company.

CEQ508, which is based on Cequent’s transkingdom RNAi technology, is designed to inhibit the oncogene beta-catenin, which is expected to prevent new polyp formation and possibly slow the progression to malignancy of existing ones.

Cequent said it expects to begin dosing patients in the study, which will take place at the Fred Hutchinson Cancer Research Center in Seattle, during the first quarter of 2010.

In the company’s proposed phase I trial, CEQ508 will be administered in escalating doses to a total of 18 adult FAP patients. “A key readout and secondary objective of the proposed trial includes analysis of … beta-catenin expression changes in the gastrointestinal tract of patients determined from biopsy samples taken prior to taking the drug, and following a daily, 28-day dosing regimen,” Cequent said.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.